X4 Pharmaceuticals Inc.
Organization details
- Legal name
- X4 Pharmaceuticals Inc.
- Former names
- Arsanis, Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Boston
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- XFOR
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001501697
- EIN
- 27-3181608
Board of directors
-
Adam R. Craig · Director · Executive ChairmanSince 2025
-
Alison Frances Lawton · DirectorSince 2023
-
Craecker Francoise De · DirectorSince 2023
-
David W. J. Mcgirr · DirectorSince 2023
-
Gary Bridger · DirectorSince 2023
-
Keith Woods · DirectorSince 2023
-
Kelly Gold · DirectorSince 2026
-
Michael S. Wyzga · DirectorSince 2023
-
Murray Stewart · Director · Interim Chief Medical OfficerSince 2023
-
Paula Ragan · Director · President and CEOSince 2023
-
William Aliski · DirectorSince 2023
Chief executives
Director election results
Annual meeting of May 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
95.4%
Board connections
6 of this board's directors also sit on 13 other boards. 13 are in the same sector.
-
CAMP4 Therapeutics Corporation Same sectorvia Murray Stewart and Paula Ragan
-
Amarin Corporation plc Same sectorvia Murray Stewart
-
Dianthus Therapeutics Inc. Same sectorvia Alison Frances Lawton
-
Insmed Incorporated Same sectorvia David W. J. Mcgirr
-
Invivyd Inc. Same sectorvia Michael S. Wyzga
-
Mereo BioPharma Group plc Same sectorvia Michael S. Wyzga
-
Neurogene Inc. Same sectorvia Keith Woods
-
ProQR Therapeutics N.V. Same sectorvia Alison Frances Lawton
-
Rhythm Pharmaceuticals Inc. Same sectorvia David W. J. Mcgirr
-
Rocket Pharmaceuticals Inc. Same sectorvia Keith Woods
-
Spyre Therapeutics Inc. Same sectorvia Alison Frances Lawton
-
TScan Therapeutics Inc. Same sectorvia Keith Woods
-
Tvardi Therapeutics Inc. Same sectorvia Michael S. Wyzga
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $11,884
- 1 purchase by 1 insider
- Sold, last 12 months
- $462,547
- 5 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 16, 2026 | Adam R. Craig Director, Officer (Executive Chairman) | Open-market purchase | +4,600 | $2.58 | $11,884 |
| Oct 1, 2026 | KIRSKE DAVID Officer (Chief Financial Officer) | Open-market sale | −11,767 | $2.86 | $33,658 |
| Aug 12, 2026 | Adam R. Craig Director, Officer (Executive Chairman) | Open-market sale | −47,436 | $4.44 | $210,616 |
| Aug 12, 2026 | Volpone John Officer (President) | Open-market sale | −24,576 | $4.44 | $109,117 |
| Jun 30, 2026 | KIRSKE DAVID Officer (Chief Financial Officer) | Open-market sale | −8,543 | $4.26 | $36,393 |
| May 12, 2026 | KIRSKE DAVID Officer (Chief Financial Officer) | Open-market sale | −16,961 | $4.29 | $72,763 |
| Oct 23, 2025 | Adam R. Craig Director, Officer (Executive Chairman) | Open-market purchase | +86,206 | $2.90 | $249,997 |
| Aug 14, 2025 | Volpone John Officer (President) | Grant or award | +289,881 | — | — |
| Aug 14, 2025 | Adam R. Craig Director, Officer (Executive Chairman) | Grant or award | +289,881 | — | — |
| Aug 14, 2025 | KIRSKE DAVID Officer (Chief Financial Officer) | Grant or award | +193,254 | — | — |
| Jun 9, 2025 | Murray Stewart Director | Grant or award | +1,500 | — | — |
| Jun 9, 2025 | Craecker Francoise De Director | Grant or award | +1,500 | — | — |
| Jun 9, 2025 | Gary Bridger Director | Grant or award | +1,500 | — | — |
| Jun 9, 2025 | Keith Woods Director | Grant or award | +1,500 | — | — |
| Jun 9, 2025 | David W. J. Mcgirr Director | Grant or award | +1,500 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about X4 Pharmaceuticals Inc.
Who is the CEO of X4 Pharmaceuticals Inc.?
Paula Ragan is X4 Pharmaceuticals Inc.'s President and CEO.
How many directors are on X4 Pharmaceuticals Inc.'s board?
X4 Pharmaceuticals Inc.'s board has 11 directors: Adam R. Craig, Alison Frances Lawton, Craecker Francoise De, David W. J. Mcgirr, Gary Bridger, Keith Woods, Kelly Gold, Michael S. Wyzga, Murray Stewart, Paula Ragan and 1 other.
Are X4 Pharmaceuticals Inc. insiders buying or selling shares?
Over the last 12 months, X4 Pharmaceuticals Inc. insiders bought $11,884 of shares in 1 purchase and sold $462,547 of shares in 5 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="x4-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.